Patents by Inventor Yikang Wang

Yikang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9675594
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 13, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors
    Publication number: 20170020850
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of Formula A: The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicants: H. Lundebck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Patent number: 9499542
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: November 22, 2016
    Assignees: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Publication number: 20160102089
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.
    Type: Application
    Filed: April 14, 2014
    Publication date: April 14, 2016
    Applicants: H. Lundbeck A/S, Vernalis (R&D) Ltd.
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
    Publication number: 20140315901
    Abstract: The present invention is directed to arylpyrrolopyridine derivatives of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease or cancer.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Inventors: Simon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
    Patent number: 8039641
    Abstract: The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidizing agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: October 18, 2011
    Assignee: Amura Therapeutics Limited
    Inventors: Martin Quibell, James Nally, Lee Patient, Yikang Wang, Claudio Dagostin, John Paul Watts
  • Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates
    Publication number: 20090192322
    Abstract: The present invention relates to a process for preparing a compound of formula (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, said process comprising the steps of: (A) (i) treating a compound of formula (IVa), where R48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Va); and (ii) converting said compound of formula (Va) to a compound of formula (Ia) or (Ic); or (B) (i) treating a compound of formula (IVb), where R48 is alkyl or tosyl, with an oxidising agent to form a compound of formula (Vb); and (ii) converting said compound of formula (Vb) to a compound of formula (Ib) or (Id).
    Type: Application
    Filed: January 8, 2009
    Publication date: July 30, 2009
    Applicant: Amura Therapeutics Limited
    Inventors: Martin Quibell, James Nally, Lee Patient, Yikang Wang, Claudio Dagostin, John Paul Watts
  • Biologically active compounds
    Publication number: 20090131502
    Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease and diseases involving matrix or cartilate degradation.
    Type: Application
    Filed: February 25, 2008
    Publication date: May 21, 2009
    Inventors: Martin Quibell, John Paul Watts, Yikang Wang, Lee Patient, Jonathan R. Heal
  • Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles
    Publication number: 20090005575
    Abstract: The present invention relates to a process for preparing a compound of formula I, wherein R1 is Pg1 or P1?; P1? is CO-hydrocarbyl; P2 is CH2, O or N-Pg2; and Pg1 and Pg2 are each independently nitrogen protecting groups; (i) reacting a compound of formula II with a dioxirane to form an epoxide of formula III; where X is selected from CN, CH2N3, CH2NH-Pg2, ONH-Pg2, NHNH-Pg2, N(Pg2)NH-Pg2; (ii) converting a compound of formula III to a compound of formula I
    Type: Application
    Filed: February 8, 2008
    Publication date: January 1, 2009
    Applicant: Amura Therapeutics Ltd.
    Inventors: Martin Quibell, Yikang Wang, James Nally, John Paul Watts, Virendar Kumar Agrawal, Michael Standen